1. 851 Potent tumor-directed T cell activation and in vivo tumor inhibition induced by a 4–1BB x 5T4 ADAPTIR™ bispecific antibody. (10th December 2020) Authors: Nelson, Michelle; Miller, Robert; Nilsson, Anneli; Ljung, Lill; Chunyk, Allison; McMahan, Catherine; Bienvenue, David; Askmyr, Maria; Hernandez-Hoyos, Gabriela; Fritzell, Sara Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A507 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 851 Potent tumor-directed T cell activation and in vivo tumor inhibition induced by a 4–1BB x 5T4 ADAPTIR™ bispecific antibody. (9th November 2020) Authors: Nelson, Michelle; Miller, Robert; Nilsson, Anneli; Ljung, Lill; Chunyk, Allison; McMahan, Catherine; Bienvenue, David; Askmyr, Maria; Hernandez-Hoyos, Gabriela; Fritzell, Sara Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A904 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies. Issue 11 (2nd November 2022) Authors: Hägerbrand, Karin; Varas, Laura; Deronic, Adnan; Nyesiga, Barnabas; Sundstedt, Anette; Ljung, Lill; Sakellariou, Christina; Werchau, Doreen; Thagesson, Mia; Gomez Jimenez, David; Greiff, Lennart; Celander, Mona; Smedenfors, Kristine; Rosén, Anna; Bölükbas, Deniz; Carlsson, Fredrika; Levin, Mattia... Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 11(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗